GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » EV-to-FCF

Hansa Biopharma AB (OSTO:HNSA) EV-to-FCF : -4.06 (As of May. 25, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hansa Biopharma AB's Enterprise Value is kr2,994.7 Mil. Hansa Biopharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was kr-736.8 Mil. Therefore, Hansa Biopharma AB's EV-to-FCF for today is -4.06.

The historical rank and industry rank for Hansa Biopharma AB's EV-to-FCF or its related term are showing as below:

OSTO:HNSA' s EV-to-FCF Range Over the Past 10 Years
Min: -130.42   Med: -21.44   Max: -1.62
Current: -3.68

During the past 13 years, the highest EV-to-FCF of Hansa Biopharma AB was -1.62. The lowest was -130.42. And the median was -21.44.

OSTO:HNSA's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs OSTO:HNSA: -3.68

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Hansa Biopharma AB's stock price is kr41.00. Hansa Biopharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-16.060. Therefore, Hansa Biopharma AB's PE Ratio for today is At Loss.


Hansa Biopharma AB EV-to-FCF Historical Data

The historical data trend for Hansa Biopharma AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB EV-to-FCF Chart

Hansa Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.17 -32.07 -6.40 -3.71 -2.00

Hansa Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.82 -3.25 -2.64 -2.00 -2.63

Competitive Comparison of Hansa Biopharma AB's EV-to-FCF

For the Biotechnology subindustry, Hansa Biopharma AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's EV-to-FCF falls into.



Hansa Biopharma AB EV-to-FCF Calculation

Hansa Biopharma AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2994.665/-736.802
=-4.06

Hansa Biopharma AB's current Enterprise Value is kr2,994.7 Mil.
Hansa Biopharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-736.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hansa Biopharma AB  (OSTO:HNSA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Hansa Biopharma AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=41.00/-16.060
=At Loss

Hansa Biopharma AB's share price for today is kr41.00.
Hansa Biopharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-16.060.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Hansa Biopharma AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansa Biopharma AB (OSTO:HNSA) Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines